4TO logo

Mainz Biomed DB:4TO Stock Report

Last Price

€8.00

Market Cap

€3.1m

7D

0%

1Y

-80.3%

Updated

24 Dec, 2024

Data

Company Financials +

4TO Stock Overview

Develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. More details

4TO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Mainz Biomed N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Mainz Biomed
Historical stock prices
Current Share PriceUS$8.00
52 Week HighUS$45.04
52 Week LowUS$6.00
Beta0.059
1 Month Change-8.26%
3 Month Change6.84%
1 Year Change-80.32%
3 Year Change-97.94%
5 Year Changen/a
Change since IPO-97.49%

Recent News & Updates

Recent updates

Shareholder Returns

4TODE BiotechsDE Market
7D0%-0.8%-1.6%
1Y-80.3%-13.0%6.8%

Return vs Industry: 4TO underperformed the German Biotechs industry which returned -13.2% over the past year.

Return vs Market: 4TO underperformed the German Market which returned 6.8% over the past year.

Price Volatility

Is 4TO's price volatile compared to industry and market?
4TO volatility
4TO Average Weekly Movement27.9%
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 4TO's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 4TO's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200868Guido Baechlermainzbiomed.com

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.

Mainz Biomed N.V. Fundamentals Summary

How do Mainz Biomed's earnings and revenue compare to its market cap?
4TO fundamental statistics
Market cap€3.05m
Earnings (TTM)-€21.66m
Revenue (TTM)€882.72k

3.5x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4TO income statement (TTM)
RevenueUS$917.20k
Cost of RevenueUS$376.25k
Gross ProfitUS$540.96k
Other ExpensesUS$23.05m
Earnings-US$22.51m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-35.19
Gross Margin58.98%
Net Profit Margin-2,453.86%
Debt/Equity Ratio-166.8%

How did 4TO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:54
End of Day Share Price 2024/12/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mainz Biomed N.V. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yi ChenH.C. Wainwright & Co.